| 25C‐NBOMe: preliminary data on pharmacology, psychoactive effects, and toxicity of a new potent and dangerous hallucinogenic drug FS Bersani, O Corazza, G Albano, G Valeriani, R Santacroce, ... BioMed research international 2014 (1), 734749, 2014 | 126 | 2014 |
| “Spice,”“kryptonite,”“black mamba”: an overview of brand names and marketing strategies of novel psychoactive substances on the web O Corazza, G Valeriani, FS Bersani, J Corkery, G Martinotti, G Bersani, ... Journal of Psychoactive Drugs 46 (4), 287-294, 2014 | 106 | 2014 |
| Tinnitus: clinical experience of the psychosomatic connection M Salviati, FS Bersani, S Terlizzi, C Melcore, R Panico, GF Romano, ... Neuropsychiatric Disease and Treatment, 267-275, 2014 | 89 | 2014 |
| Cingulate Cortex in Schizophrenia: its relation with negative symptoms and psychotic onset. A review study FS Bersani, A Minichino, M Fojanesi, M Gallo, G Maglio, G Valeriani, ... Eur Rev Med Pharmacol Sci 18 (22), 3354-3367, 2014 | 83 | 2014 |
| The diffusion of performance and image-enhancing drugs (PIEDs) on the internet: the abuse of the cognitive enhancer piracetam O Corazza, FS Bersani, R Brunoro, G Valeriani, G Martinotti, F Schifano Substance Use & Misuse 49 (14), 1849-1856, 2014 | 73 | 2014 |
| Addressing healthcare gaps in Sweden during the COVID-19 outbreak: on community outreach and empowering ethnic minority groups in a digitalized context G Valeriani, I Sarajlic Vukovic, T Lindegaard, R Felizia, R Mollica, ... Healthcare 8 (4), 445, 2020 | 64 | 2020 |
| Olanzapine as the ideal “trip terminator”? Analysis of online reports relating to antipsychotics' use and misuse following occurrence of novel psychoactive substance‐related … G Valeriani, O Corazza, FS Bersani, C Melcore, A Metastasio, G Bersani, ... Human Psychopharmacology: Clinical and Experimental 30 (4), 249-254, 2015 | 62 | 2015 |
| Facial expression in patients with bipolar disorder and schizophrenia in response to emotional stimuli: a partially shared cognitive and social deficit of the two disorders G Bersani, E Polli, G Valeriani, D Zullo, C Melcore, E Capra, A Quartini, ... Neuropsychiatric disease and treatment, 1137-1144, 2013 | 54 | 2013 |
| Adverse psychiatric effects associated with herbal weight‐loss products FS Bersani, M Coviello, C Imperatori, M Francesconi, CM Hough, ... BioMed research international 2015 (1), 120679, 2015 | 44 | 2015 |
| Psyclones: a roller coaster of life? Hidden synthetic cannabinoids and stimulants in apparently harmless products R Santacroce, O Corazza, G Martinotti, FS Bersani, G Valeriani, ... Human Psychopharmacology: Clinical and Experimental 30 (4), 265-271, 2015 | 40 | 2015 |
| Comparison of facial expression in patients with obsessive-compulsive disorder and schizophrenia using the Facial Action Coding System: a preliminary study G Bersani, FS Bersani, G Valeriani, M Robiony, A Anastasia, C Colletti, ... Neuropsychiatric Disease and Treatment, 537-547, 2012 | 32 | 2012 |
| Manic‐Like Psychosis Associated with Elevated Trough Tacrolimus Blood Concentrations 17 Years after Kidney Transplant G Bersani, P Marino, G Valeriani, V Cuoco, C Zitelli, C Melcore, ... Case Reports in Psychiatry 2013 (1), 926395, 2013 | 26 | 2013 |
| Unconventional answers to unprecedented challenges: the Swedish experience during the COVID-19 outbreak G Valeriani, IS Vukovic, R Mollica Journal of Preventive Medicine and Public Health 53 (4), 233, 2020 | 23 | 2020 |
| Premorbid circadian profile of patients with major depression and panic disorder G Bersani, FS Bersani, E Prinzivalli, L Limpido, D Marconi, G Valeriani, ... Riv Psichiatr 47 (5), 407-412, 2012 | 20 | 2012 |
| A brain centred view of psychiatric comorbidity in tinnitus: from otology to hodology M Salviati, FS Bersani, G Valeriani, A Minichino, R Panico, GF Romano, ... Neural Plasticity 2014 (1), 817852, 2014 | 19 | 2014 |
| Tackling ethnic health disparities through community health worker programs: a scoping review on their utilization during the COVID-19 outbreak G Valeriani, I Sarajlic Vukovic, FS Bersani, A Sadeghzadeh Diman, ... Population health management 25 (4), 517-526, 2022 | 18 | 2022 |
| GENERALIZED AND SPECIFIC EMOTION IMPAIRMENTS AS POTENTIAL MARKERS OF SEVERITY IN OBSESSIVECOMPULSIVE DISORDER: A PRELIMINARY STUDY USING FACIAL ACTION CODING SYSTEM (FACS) G Valeriani, F Saverio Bersani, D Liberati, E Polli, MT Girolami, D Zullo, ... Psychiatria Danubina 27 (2), 0-167, 2015 | 17 | 2015 |
| On the role of noradrenergic system in PTSD and related sleep disturbances. The use of terazosin in PTSD related nightmares: a case report M Salviati, M Pallagrosi, G Valeriani, C Carlone, L Todini, M Biondi Clin Ter 164 (2), 133-137, 2013 | 17 | 2013 |
| Coffee consumption in depressive disorders: it's not one size fits all AC Rusconi, G Valeriani, GM Carluccio, M Majorana, C Carlone, ... Rivista di psichiatria 49 (4), 164-171, 2014 | 15 | 2014 |
| Negative symptoms as key features of depression among cannabis users: a preliminary report. G BERSANI, FS BERSANI, E Caroti, P Russo, G Albano, G Valeriani, ... European Review for Medical and Pharmacological Sciences 3 (20), 537-542, 2016 | 12 | 2016 |
